Antibodies that bind notum pectinacetylesterase

Abstract

Antibodies that neutralize Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone.

1 . A monoclonal antibody that binds human notum pectinacetylesterase (NOTUM) and neutralizes at least one activity of NOTUM. 
     
     
         2 . The antibody of  claim 1 , wherein the antibody binds to a NOTUM selected from mouse NOTUM, guinea pig NOTUM, cynomolgus monkey NOTUM, and rhesus monkey NOTUM. 
     
     
         3 . The antibody of  claim 1 , wherein the antibody reduces NOTUM activity in a trisodium 8-octanoyloxypyrene-1,3,6-trisulfonate (OPTS) assay in vitro, and/or reduces NOTUM activity in a Wnt signaling assay in vitro. 
     
     
         4 . The antibody of  claim 1 , wherein upon administration to a subject the antibody increases serum Procollagen I N-terminal Propeptide (PINP) levels in vivo, increases bone mineral density in vivo, increases midshaft femur cortical thickness in vivo, increases midshaft femur bone area in vivo, increases midshaft humerus cortical thickness in vivo, increases endocortical bone formation in vivo, increases the proportion of cortical bone volume in the LV5 vertebral body in vivo, and/or increases the proportion of femoral neck bone volume to femoral neck total volume in vivo. 
     
     
         5 . The antibody of  claim 1 , wherein the antibody binds to a polypeptide having the amino acid sequence of SEQ ID NO: 1 with KD of less than 50 nM. 
     
     
         6 . The antibody of  claim 5 , wherein the KD is less than 20 nM. 
     
     
         7 . The antibody of  claim 6 , wherein the KD is less than 10 nM. 
     
     
         8 . The antibody of  claim 1 , wherein the antibody has at least one binding characteristic selected from:
 a) binds to a polypeptide having the amino acid sequence of SEQ ID NO: 83 with a binding affinity that is at least 5-fold stronger than the binding affinity of the antibody for a polypeptide having the amino acid sequence of SEQ ID NO: 84;   b) binds to a polypeptide having the amino acid sequence of SEQ ID NO: 85 with a binding affinity that is at least 5-fold stronger than the binding affinity of the antibody for a polypeptide having the amino acid sequence of SEQ ID NO: 86;   c) binds to a polypeptide having the amino acid sequence of SEQ ID NO: 1 with a binding affinity that is at least 5-fold stronger than the binding affinity of the antibody for a polypeptide having the amino acid sequence of SEQ ID NO: 94;   d) binds to a polypeptide having the amino acid sequence of SEQ ID NO: 1 with a binding affinity that is at least 5-fold stronger than the binding affinity of the antibody for a polypeptide having the amino acid sequence of SEQ ID NO: 99;   e) binds to a polypeptide having the amino acid sequence of SEQ ID NO: 95 with a binding affinity that is at least 5-fold stronger than the binding affinity of the antibody for a polypeptide having the amino acid sequence of SEQ ID NO: 2;   f) competes for binding to NOTUM with an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 15 and a light chain variable region having the amino acid sequence of SEQ ID NO: 16;   g) competes for binding to NOTUM with an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 23 and a light chain variable region having the amino acid sequence of SEQ ID NO: 24;   h) competes for binding to NOTUM with an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 31 and a light chain variable region having the amino acid sequence of SEQ ID NO: 32;   i) competes for binding to NOTUM with an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 39 and a light chain variable region having the amino acid sequence of SEQ ID NO: 40; and   j) competes for binding to NOTUM with an antibody comprising a heavy chain variable region having an amino acid sequence of SEQ ID NO: 55 and a light chain variable region having the amino acid sequence of SEQ ID NO: 56.   
     
     
         9 . The antibody of  claim 1 , wherein the antibody is selected from a mouse antibody, a chimeric antibody, a humanized antibody, and a human antibody. 
     
     
         10 .- 17 . (canceled) 
     
     
         18 . A pharmaceutical composition comprising the antibody of  claim 1 . 
     
     
         19 . A nucleic acid molecule comprising a polynucleotide sequence that encodes a heavy chain or a light chain of the antibody of  claim 1 . 
     
     
         20 . The nucleic acid molecule of  claim 19 , wherein the nucleic acid molecule comprises a first polynucleotide sequence that encodes the heavy chain, and a second polynucleotide sequence that encodes the light chain. 
     
     
         21 . The nucleic acid molecule of  claim 19 , wherein the nucleic acid molecule is a vector. 
     
     
         22 . A host cell comprising the nucleic acid molecule of  claim 19 . 
     
     
         23 . The host cell of  claim 22 , wherein the host cell comprises a first nucleic acid molecule comprising a polynucleotide sequence that encodes a heavy chain, and a second nucleic acid molecule comprising a polynucleotide sequence that encodes a light chain. 
     
     
         24 . The host cell of  claim 22 , wherein the nucleic acid molecule comprises a first polynucleotide sequence that encodes the heavy chain, and a second polynucleotide sequence that encodes the light chain. 
     
     
         25 . A method of producing an antibody comprising incubating the host cell of  claim 23  under conditions sufficient to express the antibody. 
     
     
         26 . A method of stimulating endocortical bone formation in a patient, comprising administering an effective amount of the pharmaceutical composition of  claim 18 . 
     
     
         27 . A method of treating, managing, or preventing a disease or disorder characterized by bone loss in a patient, comprising administering an effective amount of the pharmaceutical composition of  claim 18 . 
     
     
         28 . The method of  claim 27 , wherein the disease or disorder is osteoporosis. 
     
     
         29 . A single unit dosage form comprising the pharmaceutical composition of  claim 18 .